Use of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Tests by US Infectious Disease Physicians: Results of an Emerging Infections Network Survey, March 2022

Author:

Gundlapalli Adi V1,Beekmann Susan E2,Jones Jefferson M1,Thornburg Natalie J1ORCID,Clarke Kristie E N1,Uyeki Timothy M1,Satheshkumar Panayampalli S1,Carroll Darin S1,Plumb Ian D1,Briggs-Hagen Melissa1,Santibañez Scott1,David-Ferdon Corinne1,Polgreen Philip M2,McDonald L Clifford1

Affiliation:

1. COVID-19 Emergency Response Team, Centers for Disease Control and Prevention , Atlanta, Georgia , USA

2. Infectious Diseases Society of America–Emerging Infections Network and Department of Internal Medicine, University of Iowa Carver College of Medicine , Iowa City, Iowa , USA

Abstract

AbstractBackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody tests have had limited recommended clinical application during the coronavirus disease 2019 (COVID-19) pandemic. To inform clinical practice, an understanding is needed of current perspectives of United States–based infectious disease (ID) physicians on the use, interpretation, and need for SARS-CoV-2 antibody tests.MethodsIn March 2022, members of the Emerging Infections Network (EIN), a national network of practicing ID physicians, were surveyed on types of SARS-CoV-2 antibody assays ordered, interpretation of test results, and clinical scenarios for which antibody tests were considered.ResultsOf 1867 active EIN members, 747 (40%) responded. Among the 583 who managed or consulted on COVID-19 patients, a majority (434/583 [75%]) had ordered SARS-CoV-2 antibody tests and were comfortable interpreting positive (452/578 [78%]) and negative (405/562 [72%]) results. Antibody tests were used for diagnosing post–COVID-19 conditions (61%), identifying prior SARS-CoV-2 infection (60%), and differentiating prior infection and response to COVID-19 vaccination (37%). Less than a third of respondents had used antibody tests to assess need for additional vaccines or risk stratification. Lack of sufficient evidence for use and nonstandardized assays were among the most common barriers for ordering tests. Respondents indicated that statements from professional societies and government agencies would influence their decision to order SARS-CoV-2 antibody tests for clinical decision making.ConclusionsPracticing ID physicians are using SARS-CoV-2 antibody tests, and there is an unmet need for clarifying the appropriate use of these tests in clinical practice. Professional societies and US government agencies can support clinicians in the community through the creation of appropriate guidance.

Funder

Centers for Disease Control and Prevention

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Reference35 articles.

1. A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2018 update by the Infectious Diseases Society of America and the American Society for Microbiology;Miller;Clin Infect Dis,2018

2. Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP);Advisory Committee on Immunization Practices;MMWR Recomm Rep,2011

3. Immune surveillance for vaccine-preventable diseases;den Hartog;Expert Rev Vaccines,2020

4. Serological and molecular epidemiology of the dengue, Zika and chikungunya viruses in a risk area in Brazil;Mota;BMC Infect Dis,2021

5. Novel assay to measure seroprevalence of Zika virus in the Philippines;Adams;Emerg Infect Dis,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3